Psilocybin for Loneliness and Grief
What You Need to Know Before You Apply
What is the purpose of this trial?
The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.
Who Is on the Research Team?
Anahita Bassir Nia, MD
Principal Investigator
Yale University
Are You a Good Fit for This Trial?
This trial is for adults who feel lonely or are struggling with unresolved grief. Participants should be generally healthy and not have conditions that would make psilocybin unsafe, such as certain mental health disorders or medical issues.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Psilocybin
Trial Overview
The study tests whether a single dose of psilocybin (25mg) can help people feel more socially connected by reducing negative emotional responses in the brain, compared to a placebo. Participants are randomly assigned to receive either psilocybin or placebo without knowing which one they get.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
25 mg
Capsule
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yale University
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.